From what 12 stock analysts predict, the share price for Mettler-Toledo International Inc (MTD) might increase by 140265% in the next year. This is based on a 12-month average estimation for MTD. Price targets go from $1200 to $1600. The majority of stock analysts believe MTD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 12 Wall Street analysts have assignedMTD 4 buy ratings, 8 hold ratings, and 0 sell ratings. This means that analysts expect Mettler-Toledo International Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on MTD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of MTD.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Vijay Kumar Evercore ISI Group | In-Line | $1450 | Maintains | Oct 1, 2024 |
Brandon Couillard Wells Fargo | Equal-Weight | $1400 | Initiates | Aug 27, 2024 |
Daniel Arias Stifel | Buy | $1550 | Maintains | Aug 5, 2024 |
Rachel Vatnsdal JP Morgan | Neutral | $1400 | Maintains | Aug 5, 2024 |
Matthew Sykes Goldman Sachs | Neutral | $1300 | Maintains | Jul 9, 2024 |
Vijay Kumar Evercore ISI Group | In-Line | $1390 | Maintains | Jul 2, 2024 |
Tycho Peterson Jefferies | Underperform | $1250 | Assumes | Jun 3, 2024 |
Catherine Schulte Baird | Neutral | $1360 | Maintains | May 13, 2024 |
Patrick Donnelly Citigroup | Sell | $1200 | Maintains | May 13, 2024 |
Daniel Arias Stifel | Buy | $1510 | Maintains | May 13, 2024 |
Vijay Kumar Evercore ISI Group | In-Line | $1300 | Maintains | Apr 4, 2024 |
Patrick Donnelly Citigroup | Sell | $975 | Downgrade | Dec 11, 2023 |
Timothy Daley Wells Fargo | Overweight | $1300 | Maintains | Nov 13, 2023 |
Daniel Arias Stifel | Buy | $1270 | Maintains | Nov 13, 2023 |
Matthew Sykes Goldman Sachs | Neutral | $1030 | Maintains | Nov 13, 2023 |
Tycho Peterson JP Morgan | Neutral | $1100 | Maintains | Oct 17, 2023 |
Timothy Daley Wells Fargo | Overweight | $1520 | Maintains | Jul 31, 2023 |
Catherine Schulte Baird | Neutral | $1366 | Maintains | Jul 28, 2023 |
Catherine Schulte Baird | Neutral | $1454 | Maintains | May 8, 2023 |
Derik De Bruin B of A Securities | Neutral | $1525 | Maintains | May 8, 2023 |
When did it IPO
1997
Staff Count
16,000
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Patrick K. Kaltenbach
Market Cap
$29.67B
In 2023, MTD generated $3.79B in revenue, which was a decrease of -3.35% from the previous year. This can be seen as a signal that MTD's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Mettler-Toledo (MTD) is expected to report its Q3 2024 performance, with a focus on key metrics beyond standard earnings estimates.
Why It Matters - Analyzing Mettler-Toledo's key metrics beyond basic estimates can reveal growth potential, influencing investment decisions and stock valuation in the upcoming quarter.
Summary - Mettler-Toledo (MTD) is not expected to meet the criteria for a likely earnings beat in its upcoming report, according to analysts' assessments.
Why It Matters - Mettler-Toledo's earnings report may disappoint due to unfavorable conditions, potentially affecting stock performance and investor sentiment.
Summary - Mettler-Toledo International Inc. will present at three healthcare conferences in November and December 2023, with webcasts available on its investor relations website.
Why It Matters - Mettler-Toledo's participation in major healthcare conferences signals its strategic positioning and potential growth in the sector, influencing investor sentiment and stock performance.
Summary - MTD and HBIO are benefiting from robust demand in the life sciences, pharmaceutical, and academic sectors, despite a challenging macroeconomic backdrop.
Why It Matters - Strong demand in life sciences and pharmaceuticals boosts MTD and HBIO, signaling resilient growth potential amidst economic challenges, which could enhance investor confidence and stock performance.
Summary - Mettler-Toledo International Inc. (NYSE: MTD) will release Q3 2024 financial results on November 7, 2024, after market close, followed by a conference call on November 8 at 8:30 a.m. ET.
Why It Matters - Mettler-Toledo's Q3 2024 results announcement and subsequent call will provide insights into financial performance and outlook, impacting stock valuation and investor sentiment.
Summary - Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters - Zacks Style Scores provide a systematic approach to identify high-potential stocks, aiding investors in making informed decisions to enhance portfolio performance.